Literature DB >> 11398611

Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life.

D Vordermark1, M Flentje, M Sailer, O Kölbl.   

Abstract

BACKGROUND: First clinical data on a new intracavitary afterloading boost method for anal canal carcinoma is reported. PATIENTS AND METHODS: 20 consecutive patients (T1 5%, T2 70%, T3 20%, T4 5%; N0 75%, N1 10%, N2 15%; all M0) treated with external beam pelvic radiotherapy (median dose 56 Gy, range 46-64 Gy), simultaneous 5-FU and mitomycin (in 75%) and an intracavitary afterloading boost (one or two fractions of 5 Gy at 5 mm depth) were analyzed after a mean +/- SD follow-up for living patients of 4.4 +/- 2.1 years. Quality of Life (QoL) and anorectal manometry parameters were assessed in ten colostomy-free survivors.
RESULTS: Overall, recurrence-free and colostomy-free survival at 5 years were 84%, 79% and 69%, respectively. No death was tumor-related. The only local failure was successfully salvaged by local excision. All three colostomies were performed for toxicity. Resting pressure and maximum squeeze pressure of the anal sphincter were reduced by 51% and 71%, as compared with control subjects, but quality of life was similar compared to healthy volunteers.
CONCLUSION: The described regimen is highly effective but associated with increased toxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398611     DOI: 10.1007/pl00002405

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  4 in total

Review 1.  HDR brachytherapy for anal cancer.

Authors:  Peter Niehoff; Gyoergy Kovács
Journal:  J Gastrointest Oncol       Date:  2014-06

Review 2.  Systematic review: anal and rectal changes after radiotherapy for prostate cancer.

Authors:  Robin Krol; Robert Jan Smeenk; Emile N J T van Lin; Eric E K Yeoh; Wim P M Hopman
Journal:  Int J Colorectal Dis       Date:  2013-10-23       Impact factor: 2.571

3.  Interstitial high-dose rate brachytherapy as boost for anal canal cancer.

Authors:  Alexander Tuan Falk; Audrey Claren; Karen Benezery; Eric François; Mathieu Gautier; Jean-Pierre Gerard; Jean-Michel Hannoun-Levi
Journal:  Radiat Oncol       Date:  2014-11-06       Impact factor: 3.481

4.  Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).

Authors:  R Fish; C Sanders; N Ryan; S Van der Veer; A G Renehan; P R Williamson
Journal:  Colorectal Dis       Date:  2018-04-17       Impact factor: 3.788

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.